The use of a combined innovative drug for the treatment of hypertension

DOI: https://doi.org/10.29296/25877305-2019-12-09
Download full text PDF
Issue: 
12
Year: 
2019

T. Potupchik, Candidate of Medical Sciences(1); L. Evert(2), MD; O. Averyanova(3); Yu. Akhmeldinova(1) 1-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University 2-Research Institute for Medical Problems of the North, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences 3-Krasnoyarsk Interdistrict Maternity Hospital Four

The paper considers the features of using the combined innovative antihypertensive drug Amlodipine + Indapamide + Lisinopril, which can provide the target blood pressure level in patients with difficult-to-control hypertension and ensure more effective target organ protection. The active ingredients contained in Amlodipine + Indapamide + Lisinopril potentiate an antihypertensive effect, increase compliance with basic therapy, and reduce the risk of adverse effects.
Keywords: 
cardiology
hypertension
antihypertensive drugs
target blood pressure level

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Baryshnikova G.A., Stepanova I.I., Chuprova N.V. Rol' ingibitorov angiotenzinprevraschajuschego fermenta v lechenii arterial'noj gipertenzii: fokus na lizinopril // Lechaschij vrach. – 2013. [Elektronnyj resurs] Rezhim dostupa: http://www.lvrach. ru/ 2013/02/15435617/ [Baryshnikova G.A., Stepanova I.I., Chuprova N.V. Meaning of the angiotensin converting enzyme inhibitors in treatment of arterial hypertension: focus to lizinopril // Lechashchii vrach. – 2013. Available at: http://www.lvrach. ru/ 2013/02/15435617/ (in Russ.)].
  2. Gorohovskaja G.N., Petina M.M., Zav'jalova A.I. i dr. Effektivnost' i bezopasnost' lizinoprila v klinicheskoj praktike // Lechaschij vrach. – 2008; 6: 102–4 [Gorokhovskaya G.N., Petina M.M., Zav’yalova A.I. et al. Effektivnost’ i bezopasnost’ lizinoprila v klinicheskoi praktike // Lechashchii vrach. – 2008; 6: 102–4 (in Russ.)].
  3. Gosudarstvennyj reestr lekarstvennyh sredstv. Rezhim dostupa: https://grls.rosminzdrav.ru/Default.aspx [Gosudarstvennyi reestr lekarstvennykh sredstv. Available at: https://grls.rosminzdrav.ru/Default.aspx (in Russ.)].
  4. Gridina S.A., Povetkin S.V. Sravnitel'naja effektivnost' svobodnyh i fiksirovannyh kombinatsij gipotenzivnyh sredstv u bol'nyh arterial'noj gipertoniej vysokogo i ochen' vysokogo riska // Problemy zhenskogo zdorov'ja. – 2015; 3 (10): 5–11 [Gridina S.A., Povetkin S.V. The free and the fixed combinations of hypotensive drugs at patients with arterial hypertension high and very high risk // Problemy zhenskogo zdorov’ya. – 2015; 3 (10): 5–11 (in Russ.)].
  5. Diagnostika i lechenie arterial'noj gipertenzii. Rekomendatsii RMOAG i VNOK / M., 2010; 33 c. [Diagnostika i lechenie arterial’noi gipertenzii. Rekomendatsii RMOAG i VNOK / M., 2010; 33 p. (in Russ.)].
  6. Ivanenko V.V., Semenova N.V., Rjazantseva N.V. i dr. Vlijanie indapamida retard na protsessy serdechno-sosudistogo remodelirovanija u patsientov s arterial'noj gipertoniej // Arterial'naja gipertenzija. – 2003; 9 (5): 167–71 [Ivanenko V.V. , Semenova N.V., Ryazanceva N.V. et al. Effects of indapamid retard on cardiovascular remodeling processes in patients with arterial hypertension // Arterial’naya gipertenziya. – 2003; 9 (5): 167–71 (in Russ.)].
  7. Belousov Ju.B., Gurevich K.G. Klinicheskaja farmakokinetika. Praktika dozirovanija lekarstv / M., 2005; 288 s. [Belousov Yu.B., Gurevich K.G. Klinicheskaya farmakokinetika. Praktika dozirovaniya lekarstv / M., 2005; 288 p. (in Russ.)]
  8. Kobalava Zh.D., Kotovskaja Ju.V., Starostina E.G. i dr. Problemy vzaimodejstvija vracha i patsienta i kontrol' arterial'noj gipertonii v Rossii. Osnovnye rezul'taty Rossijskoj nauchno-prakticheskoj programmy ARGUS 2 // Kardiologija. – 2007; 3: 38–47 [Kobalava Zh.D., Kotovskaya Yu.V., Starostina E.G. i dr. Problemy vzaimodeistviya vracha i patsienta i kontrol’ arterial’noi gipertonii v Rossii. Osnovnye rezul’taty Rossiiskoi nauchno-prakticheskoi programmy ARGUS 2 // Kardiologiya. – 2007; 3: 47–58 (in Russ.)].
  9. Kozhanova I.N., Romanova I.S. Lizinopril v klinicheskoj praktike // Mezhdunarodnye obzory: klinicheskaja praktika i zdorov'e. – 2016; 1: 44–57 [Kozhanova I.N., Romanova I.S. Lisinopril in clinical practice // Mezhdunarodnye obzory: klinicheskaya praktika i zdorov’e. – 2016; 1: 44–57 (in Russ.)].
  10. Kutishenko N.P., Martsevich S.Ju. Lizinopril v kardiologicheskoj praktike: dannye dokazatel'noj meditsiny // Ratsional'naja farmakoterapija v kardiologii. – 2007; 3 (5): 79–82 [Kutishenko N.P., Martsevich S.J. Lisinopril usage in cardiologic practice: data of evidence based medicine // Rational Pharmacotherapy in Cardiology. – 2007; 3 (5): 79–82 (in Russ.)]. https://doi.org/10.20996/1819-6446-2007-3-5-66-69.
  11. Leonova M.V. Sovremennyj vzgljad na amlodipin i novye preparaty s-amlodipina // Ratsional'naja farmakoterapija v kardiologii. – 2011; 7 (2): 227–30 [Leonova M.V. Contemporary sight at amlodipine and new drugs of s-amlodipine // Rational Pharmacotherapy in Cardiology. – 2011; 7 (2): 227–30 (in Russ.)]. https://doi.org/10.20996/1819-6446-2011-7-2-227-230.
  12. Martsevich S.Ju. Antagonisty kal'tsija – printsipy terapii v svete dannyh dokazatel'nyh issledovanij // RMZh. – 2003; 27: 1542–5 [Martsevich S.Yu. Antagonisty kal’tsiya – printsipy terapii v svete dannykh dokazatel’nykh issledovanii // RMZh. – 2003; 27: 1542–5 (in Russ.)]
  13. Podzolkov V.I., Platonova M.V., Bulatov V.A. Klinicheskaja effektivnost' indapamida u bol'nyh gipertonicheskoj bolezn'ju // RMZh. – 2001; 10: 433–8 [Podzolkov V.I., Platonova M.V., Bulatov V.A. Klinicheskaya effektivnost’ indapamida u bol’nykh gipertonicheskoi bolezn’yu // RMZh. – 2001; 10: 433–8 (in Russ.)].
  14. Preobrazhenskij D.V., Nekrasova N.I., Talyzina I.V. i dr. Lizinopril – gidrofil'nyj ingibitor angiotenzinprevraschajuschego fermenta dlitel'nogo dejstvija: osobennosti klinicheskoj farmakologii i diapazon klinicheskogo primenenija // RMZh. – 2010; 10: 684–9 [Preobrazhenskii D.V., Nekrasova N.I., Talyzina I.V. i dr. Lizinopril – gidrofil’nyi ingibitor angiotenzinprevrashchayushchego fermenta dlitel’nogo deistviya: osobennosti klinicheskoi farmakologii i diapazon klinicheskogo primeneniya // RMZh. – 2010; 10: 684–9 (in Russ.)].
  15. Rekomendatsii po lecheniju arterial'noj gipertonii. ESH/ESC 2013 // Rossijskij kardiologicheskij zhurnal. – 2014; 1: 7–94 [2013 ESH/ESC Guidelines for the management of arterial hypertension // Rossiiskii kardiologicheskii zhurnal. – 2014; 1: 7–94 (in Russ.)].
  16. Sazonova A. Novye napravlenija v bor'be s arterial'noj gipertenziej // Provizor. – 2007; 7: 24–7 [Sazonova A. Novye napravleniya v bor’be s arterial’noi gipertenziei // Provizor. – 2007; 7: 24–7 (in Russ.)].
  17. Safronenko A.V., Makljakov Ju.S., Vystavkina E.A. i dr. Tserebro- i nefroprotektivnye svojstva kombinatsii antigipertenzivnyh i metabolicheskih preparatov pri lechenii refrakternoj arterial'noj gipertenzii // Ural'skij meditsinskij zhurnal. – 2012; 5 (97): 114–7 [Safronenko A.V., Maklyakov Yu.S., Vystavkina E.A. et al. Cerebro-and nephroprotektiv properties of combinations of antihypertensive and metabolic preparations in treating resistant hypertension // Ural’skii meditsinskii zhurnal. – 2012; 5 (97): 114–7 (in Russ.)].
  18. Ckvortsov V.V., Tumarenko A.V., Orlov O.V. i dr. Sovremennye aspekty kombinirovannoj antigipertenzivnoj terapii // Terapevt. – 2009; 7: 41–7 [Ckvortsov V.V., Tumarenko A.V., Orlov O.V. i dr. Sovremennye aspekty kombinirovannoi antigipertenzivnoi terapii // Terapevt. – 2009; 7: 41–7 (in Russ.)].
  19. Strilets O.P., Trutaev I.V., Strel'nikov L.S. Razrabotka metodiki kolichestvennogo analiza mnogokomponentnogo antigipertenzivnogo preparata // Ukraїns'kij zhurnal klinichnoї ta laboratornoї meditsini. – 2011; 3 (6): 152–5 [Strilets O.P., Trutaev I.V., Strel’nikov L.S. Razrabotka metodiki kolichestvennogo analiza mnogokomponentnogo antigipertenzivnogo preparata // Ukraїns’kii zhurnal klinichnoї ta laboratornoї meditsini. – 2011; 3 (6): 152–5 (in Russ.)].
  20. Har'kov E.I., Davydov E.L. Ekonomicheskaja effektivnost' terapii gipertonicheskoj bolezni v pozhilom vozraste // Sibirskoe meditsinskoe obozrenie. – 2006; 6 (43): 70–5 [Khar’kov E.I., Davydov E.L. The economic and clinical effectiveness of therapy in hypertension in elderly age // Sibirskoe meditsinskoe obozrenie. – 2006; 6 (43): 70–5 (in Russ.)].
  21. Jakovleva E.V. Vlijanie mnogokomponentnoj terapii na agregatsionnuju aktivnost' trombotsitov u bol'nyh s revmatoidnym artritom v sochetanii s arterial'noj gipertoniej // Kubanskij nauchnyj meditsinskij vestnik. – 2010; 8 (122): 196–9 [Yakovleva E.V. Influence of multicomponent therapy on aggregation properties of thrombocytes by patients with rheumatoid arthritis in a combination ith arterial hypertension // Kubanskii nauchnyi meditsinskii vestnik. – 2010; 8 (122): 196–9 (in Russ.)].
  22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. – 2002; 288: 2981–97.
  23. De Backer G., Ambrosioni E., Borch-Johnses K. et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) // Eur. Heart J. – 2003; 24 (17): 1601–19.
  24. Filippi A., Paolini I., Innocenti F. et al. Blood pressure control and drug therapy in patients with diagnosed hyper’ tension: a survey in Italian general practice // Hum. Hypertens. – 2009; 23 (11): 758–63.
  25. Giannettasio C., Grassi G., Seravalle G. et al. Guidelines for the diagnosis and treatment of chronic heart failure (2005) // Rational Pharmacotherapy in Cardiology. – 2006; 2 (2): 71–101.
  26. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricularfunction after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nel-l’Infarto Miocardico // Lancet. – 1994; 343: 1115–22.
  27. Goldmann S., Stoltefuss J., Born L. Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction // J. Med. Chem. – 1992; 35: 3341–4.
  28. Hernamdez R., Armas-Hernamdez M., Zafar H., et al. Calcium antagonists and atherosclerosis protection in hypertension // Am. J. Ther. – 2003; 10 (6): 409–14.
  29. Mason R., Rhodes D., Herbette L. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes // J. Med. Chem. – 1991; 34 (3): 869–77.
  30. Mital S., Magneson A., Loke K. et al. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts // J. Cardiovasc. Pharmacol. – 2000; 36: 248–54.
  31. Mori H., Ukai H., Yamamoto H. et al. Current status of antihypertensive prescription and associated blood pressure control in Japan // Hypertens Res. – 2006; 29 (3): 143–51.
  32. Packer M., Poole-Wilson P., Armstrong P. et al. Comparative effects of low and high doses of the angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group // Circulation. – 1999; 100: 2312–8.
  33. Phillips J., Mason R. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions // Atherosclerosis. – 2003; 168 (2): 239–44.
  34. Reisin E., Weir M., Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group // Hypertension. – 1997; 30 (Pt. 1): 140.
  35. Reja A., Tesfaye S., Harris N. et al. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? // Diabet Med. – 1999; 12: 307–9.
  36. Perez Zamora S., Benitez Camps M., DalfoBaque A. et al. Is the action taken by Catalonian primary care doctors adequate in view of the insufficient reduction in blood pres’ sure levels in hypertensive patients? DISEHTAC’2001 study // Aten Primaria. – 2008; 40 (10): 505–10.
  37. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension // J. Hypertens. – 2007; 25: 1105–87.
  38. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high’risk hypertensive patients randomized to angiotensin’converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid’Lowering treatment to prevent Heart Attack Trial (ALLHAT) // JAMA. – 2002; 288 (23): 2981–97.
  39. Williams K., Michael P., Freeman G. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects // Arthr. Rheum. – 2003; 48 (7): 1833–40.
  40. Zhang X.-P., Xu X., Nasjletti A. et al. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels // J. Cardiovasc. Pharmacol. – 2000; 35: 195–202.
  41. Zhang X.-P., Loke K., Mital S. et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R-enantiomer of amlodipine // J. Cardiovasc. Pharmacol. – 2002; 39: 208–14.
  42. Zhang X.-P., Mital S., Hintze T. Angiotensin AT2 and AT4 receptor blockade prevents amlodipine and its R-enantiomer stimulated endothelial nitric oxide production (Abstract) // Circulation. – 2001; 104 (suppl. II): II-33.
  43. Zee R., Stephen A., Iwai N. Association analysis of Sa gene variant in essential hypertensives // Am. J. Hypertens. – 2007; 10: 235–42.